DICE Therapeutics
Debasish Raha's work experience includes a role as Director of Biomarker and Translational Sciences at DICE Therapeutics starting in 2022. Prior to that, they worked at Cortexyme, Inc. from 2017 to 2022, holding positions as Associate Director of Translational Research and Biomarker Development, as well as Principal Scientist. At Cortexyme, they focused on translational research, biomarker discovery, and biomarker assay development for neurodegenerative disorders. Debasish also contributed to the biomarker section in an IND pharmacology-written-summary. Before joining Cortexyme, Debasish was a Senior Scientist at CytomX Therapeutics in 2016 and a Senior Scientist II at Onyx Pharmaceuticals, Inc. from 2014 to 2015. From 2010 to 2013, they worked as a Scientific Manager at Genentech, MDCCB, studying non-genetic and genetic mechanisms of resistance to targeted cancer therapies. Debasish's earliest work experience was at Yale University, where they served as a Research Scientist and Manager for the Human ENCODE Project from 2007 to 2010. In this role, they managed research activities and production work related to the identification of regulatory elements of the human genome. Debasish also played a role in developing protocols for ChIP Seq and RNA Seq.
Debasish Raha has a strong educational background in the field of science. Debasish obtained a Bachelor of Science degree in Chemistry from the University of Calcutta. Following this, they pursued a Master of Science degree in Biochemistry at the same institution. Finally, they completed their education with a PhD in Molecular Biology from Bose Institute in India.
DICE Therapeutics
At DICE Therapeutics, we design and develop innovative therapies in immunology for patients with debilitating disease. Seeking to create a future where convenient oral medicines with biologic-like efficacy are available to patients with serious medical conditions, we are developing oral alternatives to medicines currently limited to injectable forms. We believe that such pills will be widely appreciated by patients and doctors alike, as they provide a lower bar to entry than biologics, and as oral medicines can easily be co-formulated with other efficacious drugs. The combination of our core technology with additional, unique biophysical insights has enabled DICE to target protein-protein interactions with small molecules. In doing so, DICE has cracked open a previously intractable set of clinically validated therapeutic targets, including Interleukin-17 (IL-17). Our lead program – an orally bioavailable IL-17 antagonist for the treatment of psoriasis – is currently progressing through IND-enabling studies. In parallel, we continue to advance both partnered and internal pipeline drug discovery programs, providing a robust pre-clinical pipeline.